Academic case study on Nav1.9 as a drug target by Associate Professor David Bulmer (University of Cambridge). Overview of Metrion’s newly developed Nav1.9 screening assays by Metrion CSO, Dr. Eddy Stevens.
Dr. Kris Kahlig is the Head of Biology at Praxis Precision Medicines Inc. a clinical stage biopharmaceutical company translating genetic insights into the development of therapies for patients affected by CNS disorders. Kris presented at the Metrion Webinar series on “Using Dynamic Action Potential Clamp Modelling of Nav1.2 Variants to Support the Prediction of Clinical Phenotype in DEE”.
The webinar took place on Thursday 5th May 2022 at 16:00 BST.
Academic case study on Nav1.9 as a drug target by Associate Professor David Bulmer (University of Cambridge). Overview of Metrion’s newly developed Nav1.9 screening assays by Metrion CSO, Dr. Eddy Stevens.
Alex Haworth, Senior Scientist at Metrion, introduces a poster demonstrating Metrion's development of a monoclonal CHO cell line expressing hNav1.9, validated via manual and automated patch clamp techniques.